Research suppliers and buyers for any molecule, in any market, with a source for every claim.
Map every credible supplier for your molecules, from APIs to CDMOs to contract manufacturers, with a source for every claim. Pick who to meet; we make the introduction.
Map your suppliers →Rank every buyer for your molecule in any market: who to call, in what order, and why now. Ranked targets, price history, and the people to talk to.
Map your buyers →Both reports come from the same data graph, and every claim links to its source. The example below is real: sacubitril/valsartan, a heart failure blockbuster whose US compound patent expired in 2025. Click through the tabs; every screen is from an actual run in the product.
Type the molecule you need and the market you buy for. The AI research agent checks every credible manufacturer and builds the finished report.
No supplier yet holds an in-market credential for the finished sacubitril/valsartan combination in the United States, so this lane is worth a request-for-information round with the combination-DMF holders rather than a purchase order right now; one supplier is currently blocked from this market, and the freedom-to-operate position is covered in Section 4.
India anchors the deepest credentialed base and carries most of the combination-level filers, while China contributes broad API-only volume including one combination-level filer and the market's one blocked entry, Zhejiang Huahai.s2s72
The single home for intellectual property and freedom-to-operate findings on this map.
| Number | Juris. | Claim type | Status | Expiry |
|---|---|---|---|---|
| 10722471 | US | formulation | active | 2 Feb 2037 |
| 11058667 | US | method | active | 9 May 2036 |
| 9937143 | US | method | active | 22 Aug 2033 |
| 8877938 | US | compound | active | 27 May 2027 |
| 11,096,918 | US | polymorph | active | 9 Nov 2026 |
| 9388134 | US | method | active | 8 Nov 2026 |
| 8,101,659 | US | method | expired | 15 Jul 2025 |
A trader is an access route, not a qualifiable site. These entries receive no tier.
Every supplier surfaced for this map was confirmed as a manufacturer, so they sit in the Directory rather than here. Access channels list distributors, agents, and traders who resell rather than make; none applied to this map. For direct sourcing this is the preferred outcome, because there is no middleman margin to price in.
Two modelled reads, neither demand nor a quote: how many patients the molecule could serve, and what the active ingredient costs to buy. A firm price, MOQ, and lead time come back in the RFI.
A Request for Information is a prefilled question sheet, one per supplier, built from the cells that could not be confirmed from public data. Send it to close the gaps: firm price, MOQ, lead time, and site details.
Type what you sell and the market you want to enter. The app ranks every company that could buy it and builds the campaign.
The evidence base for this lane is thin. No addressable market size is on file, no price band met the minimum sample size, and no exporter share data is on file, so the size and the price ceiling of the United States API opportunity cannot be assessed from this record. The only substantive datapoint is a pending compound patent in Switzerland with an expiry of 2030-09-16.
131 people across 46 of 109 buyers, in outreach order.
| Person | Title | Company |
|---|---|---|
| Beth Hamilton | VP, National Accounts | #1 ASCEND LABORATORIES |
| Gajanan Thorat | CEO, Torrent Pharma Inc | #2 TORRENT PHARMA |
| Venkatesh Srinivasan | Chief Executive Officer | #3 NOVADOZ PHARMA |
| Milan Kalawadia | CEO, North America | #4 DR REDDY'S PTY |
| Krishna Setty | Director | #5 CAMBER PHARMA |
| Venumadhav Madamanchi | Chief Procurement Officer | #8 MYLAN PHARMA |
Triggers surface as filings change, each with its source.
An answer you cannot check is worth nothing in a regulated industry. PharmaDB reads the registers directly, cites the record behind each line, and marks the fields it could not confirm rather than filling them in.
One data graph, built from 64 national and regional regulators across 135+ countries, 10+ patent offices, and the records around them.
The same five labels run through both map types, so you always know how much weight a line can hold before you act on it.
The sacubitril/valsartan map above was built from 77 of these records, and each one is one click from the claim it supports.
Five databases, per country, per molecule. Checking one supplier properly takes days, and checking a whole market takes weeks.
Self-listed and seller-paid. A listing proves a company wants to sell, not that it can supply your market.
Weeks of lead time and a fee per question, with conclusions you cannot trace back to a source.
A PharmaDB map is built in minutes, is self-serve from day one, and cites the record behind every claim. No demo call.
A report on every credible manufacturer of a molecule for the market you buy for. Credentials are checked against the public registers, patents and reference prices sit alongside, and every claim links to its source.
The same research pointed the other way: every company that could buy the molecule you sell in a target market, ranked and tiered, with the people to contact and the reason each buyer fits.
From the public record: 64 national and regional regulators, patent offices, GMP and inspection registers, public tenders and company registries across 135+ countries. The Sources tab of every map lists the exact records used.
No. Nobody can pay their way into a map. Rankings follow the evidence in the registers, and the map shows that evidence next to every placement.
No. What you research on PharmaDB is never visible to anyone else. Maps are built from public records, not from other users’ activity.
You pick the suppliers you want to meet, and we reach out, present your requirement, and hand you the conversation when they respond. Connecting with suppliers is included on paid plans.
You can start for free. Paid plans and exactly what they include are on the pricing page.